Rhythm is excited to announce that the FDA has accepted our supplemental New Drug Application for patients as young as 2 years old living with obesity due to Bardet-Biedl syndrome or POMC/LEPR deficiency. For details, see our press release: https://lnkd.in/eJH-SYqm
Rhythm Pharmaceuticals Inc.
Biotechnology Research
Boston, MA 29,613 followers
Über uns
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare MC4R pathway diseases. The company is leveraging the Rhythm Engine -- comprised of its TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.RareObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information.
- Website
-
http://www.rhythmtx.com
External link for Rhythm Pharmaceuticals Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Boston, MA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2008
- Spezialitäten
- genetics, obesity, peptides, metabolism, rare disease, biotechnology, Pharmaceuticals, Research, Health, Medicine, Clinical Trials, Endocrinology, Orphan disease, Science, Advocacy, Epidemiology, Orphan drugs, Rare disease, and metabolic
Standorte
-
Primäre
Wegbeschreibung erhalten
222 Berkeley Street, 12th Floor
Boston, MA 02116, US
Employees at Rhythm Pharmaceuticals Inc.
Aktualisierungen
-
Rhythm President and CEO David Meeker, M.D., will discuss Rhythm’s efforts to transform the care of patients with #hyperphagia and severe #obesity caused by rare MC4R pathway diseases at the Canaccord Genuity Annual Growth Conference on Tuesday, August 13, 2024, at 11:00 a.m. ET in Boston, MA. Learn more here: https://lnkd.in/ef2hryiC
-
-
Rhythm hosted a conference call on Tuesday and discussed second quarter 2024 financial results and recent business updates, including US commercial sales and the latest on our progress in Europe, clinical trial milestones and more. You can watch the recording here: https://lnkd.in/e37WzkiM
-
-
Rhythm President and CEO David Meeker, M.D., will discuss Rhythm’s efforts to transform the care of patients with #hyperphagia and severe #obesity caused by rare MC4R pathway diseases at the Canaccord Genuity Annual Growth Conference on Tuesday, August 13, 2024, at 11:00 a.m. ET in Boston, MA. Learn more here: https://lnkd.in/ef2hryiC
-
-
Rhythm will host a conference call on Tuesday, August 6 at 8 a.m. to discuss second quarter 2024 financial results and recent business updates. For details, see our press release: https://lnkd.in/ef2hryiC
-
-
Stories from the rare MC4R pathway disease community continue to inspire our work to transform the lives of patients and their families affected by hyperphagia and severe #obesity. Learn more about our focus on rare MC4R pathway diseases: https://rhythmtx.com/
-
-
We are excited to announce the appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer of Rhythm Pharmaceuticals! https://lnkd.in/e698tNAP
-